Denali Therapeutics Inc.
161 Oyster Point Boulevard
South San Francisco
California
94080
United States
Website: http://www.denalitherapeutics.com/
Email: contact@dnli.com
132 articles about Denali Therapeutics Inc.
-
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
6/10/2020
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). -
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
6/9/2020
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced the results from its Phase 1b studies with small molecule RIPK1 inhibitor DNL747 in Alzheimer’s disease and ALS, and provided a broad RIPK1 program update including DNL788 and DNL758.
-
In a paper published on Wednesday, Denali detailed the engineering of its transport vehicles.
-
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
5/27/2020
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced publication of two papers in Science Translational Medicine (“STM”).
-
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
5/7/2020
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, reported financial results for the first quarter ended March 31, 2020 and provided an update on the Company's response to COVID-19.
-
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
4/2/2020
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today provided an update on the expected pipeline and business impact from the COVID-19 pandemic.
-
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
2/27/2020
Denali Therapeutics Inc. (NASDAQ: DNLI), today reported financial results for the fourth quarter and full year ended December 31, 2019, and provided business highlights.
-
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/1/2020
Denali Therapeutics Inc. announced the closing of its upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $23.00 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares.
-
Denali Therapeutics Announces Pricing of Public Offering of Common Stock - Jan. 28, 2020
1/29/2020
Denali Therapeutics Inc. announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share.
-
Denali Therapeutics Announces Proposed Offering of Common Stock
1/27/2020
Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock
-
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
1/14/2020
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced the results of its Phase 1b clinical trial of LRRK2 inhibitor DNL201 in patients with Parkinson’s disease and its Phase 1 clinical trial of LRRK2 inhibitor DNL151 in healthy volunteers.
-
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
11/6/2019
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, reported financial results for the third quarter ended September 30, 2019, and provided business highlights.
-
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
-
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
-
We thought it would be insightful to look back at our previous lists to see where some of those companies are today. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2017.
-
AbCellera and Denali Therapeutics Sign Expanded Multi-Year, Multi-Target Deal to Discover Therapeutic Antibodies for Neurological Diseases
2/28/2019
AbCellera announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications.
-
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
-
SIRION Biotech and Denali Therapeutics Join Forces to Develop Gene Therapies for Diseases of the Central Nervous System
1/9/2019
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Denali Therapeutics (NASDAQ: DNLI),
-
Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.
-
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.